pembrolizumab (keytruda) Report issue

Biologics mAb Orphan Drug FDA Approved FDA First in Class Accelerated Approval FDA Priority Review FDA
Back

Drug Pricing Summary

AUS PBS

$3120.5825

VA Big4

$3569.3400 - $3619.2550

VA FSS

$4721.6200 - $4792.4300

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
pembrolizumab 100 mg / 4 mL (INJECTION) $3120.5825 AUS PBS generic
  • Keytruda (1)
  • Merck Sharp & Dohme (Australia) Pty Ltd
    pembrolizumab 25 mg / 1 mL (1 mL INJECTION) $3569.3400 VA Big4
  • KEYTRUDA (1)
  • Merck Sharp & Dohme Corporation
    pembrolizumab 25 mg / 1 mL (1 mL INJECTION) $3619.2550 VA Big4
  • KEYTRUDA (2)
  • Merck Sharp & Dohme Corporation
    pembrolizumab 25 mg / 1 mL (1 mL INJECTION) $4721.6200 VA FSS
  • KEYTRUDA (1)
  • Merck Sharp & Dohme Corporation
    pembrolizumab 25 mg / 1 mL (1 mL INJECTION) $4792.4300 VA FSS
  • KEYTRUDA (2)
  • Merck Sharp & Dohme Corporation

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue